SEARCH

SEARCH BY CITATION

References

  • 1
    Truelove SC, Willoughby Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; ii: 1086 8.
  • 2
    Marion JF & Present DH. The modern medical management of acute, severe ulcerative colitis. Eur J Gastroenterol Hepatol 1997; 9: 831 5.
  • 3
    Lennard Jones JE. Defining ulcer depth in colitis. Lancet 1996; 347: 17081708.
  • 4
    Murch SH & Walker-Smith JA. Medical therapy of chronic inflammatory bowel disease. Baillière’s Clin Gastroenterol 1994; 8: 133 48.
  • 5
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423 33.
  • 6
    Markowitz J, Grancher K, Mandel F, Daum F. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive use of the Pediatric IBD Collaborative Research Forum. Am J Gastroenterol 1993; 88: 44 8.
  • 7
    D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 1997; 112: 1475 81.
  • 8
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215 9.
  • 9
    Mahdi G, Israel DM, Hassall E. Cyclosporine and 6-mercaptopurine for active, refractory Crohn’s colitis in children. Am J Gastroenterol 1996; 91: 1355 9.
  • 10
    Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971; ii: 1273 6.
  • 11
    Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847 69.
  • 12
    Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 1993; 105: 367 72.
  • 13
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double blind study. New Engl J Med 1980; 302: 981 7.
  • 14
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine in Crohn’s disease. A meta-analysis. Ann Int Med 1995; 122: 132 42.
  • 15
    Van Sandborn Wjoec, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease. Gastroenterology 1995; 109: 1808 17.
  • 16
    Cuffari C, Theoret Y, Latour S, Seidman G. 6-mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996; 39: 401 6.
  • 17
    Sandborn WJ Selected Summaries. Comment on Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996; 39: 401 6. Gastroenterology 1997; 113: 690 2.
  • 18
    Kerstens Pjsm, Stolk JN, Boerbooms AMT, De Abreu RA, Van De Putte LBA. Purine enzymes in rheumatoid arthritis. A clue to the prediction of the response to azathioprine? review and hypothesis. Clin Exp Rheumatol 1995; 13: 107 11.
  • 19
    Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 674 8.
  • 20
    Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor-alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913 7.
  • 21
    Alamartine E, Sabido O, Berthoux F. In-vitro effects of cyclosporin A, FK506, 6–mercaptopurine and prednisolone on lymphokine–activated killer cells. Nephrol Dialys Transplant 1994; 9: 1456 61.
  • 22
    Calne RY, Alexander GPJ, Murray JE. A. study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann NY Acad Sci 1962; 99: 743 61.
  • 23
    Kretensky TA, Hall WW, Selph JL, Truax JF, Vinegar R. Nucleosides of azathioprine and thiamiprine as antiarthritics. J Med Chem 1989; 32: 1471 5.
  • 24
    Crawford DJ, Maddocks JL, Jones DN, Szawlowski P. Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J Med Chem 1996; 39: 2690 5.
  • 25
    Beattie RM, Nicholls SW, Domizio P, Williams CB, Walker-Smith JA. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Paediatr Gastroenterol Nutr 1996; 22: 373 9.
  • 26
    Modigliani R, Mary JY, Simon JF, Cortot a Soule JC, Gendre JP, Rene E. Clinical biological and endoscopic picture or attacks of Crohn’s disease. Evolution on prednisolone. Gastroenterology 1990; 98: 811 8.
  • 27
    D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 1997; 112: 1475 81.
  • 28
    Walker-Smith JA. Mucosal healing in Crohn’s disease. Gastroenterology 1998; 114: 419 20.